Skip to main content
Clinical Trials/NCT00270959
NCT00270959
Completed
Phase 1

Early Combined Intervention After Traumatic Injury

University of Washington1 site in 1 country207 target enrollmentJune 2006

Overview

Phase
Phase 1
Intervention
Cognitive Behavioral Therapy
Conditions
Post-Traumatic Stress Disorder
Sponsor
University of Washington
Enrollment
207
Locations
1
Primary Endpoint
Substance use
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

This study will evaluate the effectiveness of patient-centered collaborative care that combines behavioral therapy and drug therapy as compared to usual care in reducing symptoms of post-traumatic stress disorder in people who have survived a traumatic injury.

Detailed Description

Approximately 2.5 million people in the U.S. are hospitalized each year having sustained injuries during a traumatic event. Injured trauma survivors are at high risk for developing post-traumatic stress disorder (PTSD) and other related conditions. In addition, many of these people experience several physical, financial, social, legal, and medical problems over the course of the year following the trauma. Effective interventions to prevent or remedy these issues have yet to be developed for individuals who undergo inpatient surgery following a traumatic injury and who then continue with outpatient treatment and community rehabilitation. This study will evaluate the effectiveness of patient-centered collaborative care that combines behavioral therapy and drug therapy as compared to usual care in reducing symptoms of PTSD and substance use. The study will also assess the intervention's effectiveness in increasing participants' general functioning and satisfaction with their care post-injury. Participants in this open label study will be randomly assigned to receive either the standard care provided to injured trauma survivors or a combination of behavioral therapy and drug therapy. Participants assigned to receive the combination therapy may receive one or more of the following medications based on their individual needs: fluoxetine; sertraline; paroxetine; buspirone; propranolol; trazodone; and any of the benzodiazepines. Participants may begin receiving medication immediately or anytime within the 12 months post-injury. Behavioral therapy will also be administered on the basis of the participants' individual needs and may continue for up to 12 months. Participants will also take part in motivational interviews, the first of which will be conducted upon study entry in the hospital ward. Subsequent interviews will be conducted over the phone at Months 1, 3, 6, 9, and 12. Participants will be required to report to the study site only for the initial baseline visit. Outcome measures will include PTSD severity ratings, frequency of substance use, and general functioning reports.

Registry
clinicaltrials.gov
Start Date
June 2006
End Date
March 2013
Last Updated
5 years ago
Study Type
Interventional
Study Design
Factorial
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Douglas Zatzick

Professor

University of Washington

Eligibility Criteria

Inclusion Criteria

  • English-speaking
  • Admitted to Harborview Medical Center with injuries sufficiently severe to require inpatient admission
  • Experienced a traumatic injury
  • Exhibits symptoms of PTSD while in the hospital ward

Exclusion Criteria

  • History of head, spinal, or other injury that may prevent participation in the ward interview
  • Requires immediate intervention due to conditions such as self-inflicted injury, active psychosis, or active mania
  • Currently incarcerated
  • Likely to face criminal charges
  • Lives more than 50-100 miles from Harborview Medical Center

Arms & Interventions

1

Stepped collaborative care (combination of behavioral therapy and drug therapy)

Intervention: Cognitive Behavioral Therapy

1

Stepped collaborative care (combination of behavioral therapy and drug therapy)

Intervention: Motivational Interviewing

1

Stepped collaborative care (combination of behavioral therapy and drug therapy)

Intervention: FDA-Approved Anti-Anxiety Medications

2

Standard care provided to injured trauma survivors

Intervention: Standard Care Control

Outcomes

Primary Outcomes

Substance use

Time Frame: Measured at Year 1

General functioning reports

Time Frame: Measured at Year 1

PTSD ratings

Time Frame: Measured at Year 1

Secondary Outcomes

  • Increased satisfaction with global care(Measured at Year 1)
  • Injury relapse(Measured at Year 5)
  • Work, disability, and legal outcomes(Measured at Year 1)

Study Sites (1)

Loading locations...

Similar Trials